Europe Venous Thromboembolism Epidemiology and Patient Flow Analysis - 2017
Fore Pharma announced the results of its Venous Thromboembolism patients study in a new report ‘Europe Venous Thromboembolism Epidemiology and Patient Flow Analysis - 2017’. The report provides insights into Venous Thromboembolism epidemiology, Venous Thromboembolism diagnosed patients, and Venous Thromboembolism treatment rate for EU5 pharmaceutical markets. The study measures key indicators such as prevalence of Venous Thromboembolism derived from epidemiological analysis, percentage of patients diagnosed with Venous Thromboembolism, and percentage of patients treated with a therapy.
The study helps executives estimate Venous Thromboembolism market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Venous Thromboembolism prevalence, Venous Thromboembolism diagnosis rate, and Venous Thromboembolism treatment rate for the period 2016 - 2025. The information is presented by leading geographies including Germany, France, Spain, Italy, and UK. The study design is based on interpretation and analysis of data collected from physicians via primary interviews, registries, scientific journals, literatures, government databases and other secondary sources.